1) Kambe T., Tsuji T., Hashimoto A. and Itsumura N. The Physiological, and molecular rules of zinc transporter in zinc homeostasis and metabolism., Physiol. Rev., 2015, 95, 749-784.
2) Andreini C., Banci L., Bertini I., Rosato A. Counting the zinc-proteins encoded in the human genome., J. Proteome Res., 2006, 5, 196-201.
3) Maret W. Zinc biochemistry: from a single zinc enzyme to a key element of life., Adv. Nutr., 2013, 4, 82-91.
4) Andriini C. and Bertini I. A bioinformatics view of zinc enzymes., J. Inorg. Biochem., 2012, 111, 150-156.
5) Vallee B. L. and Auld D.S. Zinc coordination, function and structure of zinc enzyme and other proteins., Biochemistry, 1990, 29, 5647-5659.
6) Vallee B. L.and Falchuk K.H. The biochemical basis of zinc physiology., Physiol. Rev., 1993, 73, 79-118.
7) Scott D.A. Crystalline insulin., Biochem. J., 1934, 28, 1592-1602.
8) Blundell T. L., Cutfield J. F., Cutfield S. M., Dodson E. J., Dodson G. G., Hodgkin D. C. and Mercola D. A. Three-dimensional atomic structure of insulin and its relationship to activity., Diabates, 1972, 21, 492-505.
9) Emdin S. O., Dodson G. G., Cutfield J. F. and Cutfield S. M. Role of zinc in insulin biosynthesis. some possible zinc-insulin interaction in the pancreatic B-cell., Diabatologia, 1980, 19, 174-182.
10) Hutton J.C. The insulin secretory granule., Diabetologia, 1989, 32, 271-281.
11) Criszak E. and Smith G. D. Crystallographic evidence for dual coordination around zinc in the T3R3 human insulin hexamer., Biochemistry, 1994, 33, 1512-1517.
12) Miller J., McLachlan A.D. and Klug A. Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes., EMBO J., 1985, 4, 1609-1614.
13) Ganss B. and Jheon A. Zinc finger transcription factors in skeletal development., Crit. Rev. Oral Biol. Med., 2004, 15, 282-297.
14) Laity J. H., Lee M. and Wright P. E. Zinc finger proteins: new insights into structural and functional diversity., Curr. Opin. Struct. Biol., 2001, 11, 39-46.
15) Browns R. S. Zinc finger proteins; getting a grip on RNA., Curr. Opin. Struct. Biol., 2005, 15, 94- 98.
16) Hall T. M. Multiple modes of RNA recognition by zinc finger proteins., Curr. Opin. Struct. Biol., 2005, 15, 367-373.
17) Andriini C., Bertini I. and Cavallaro G. Minimal functional sites allow a classification of zinc sites in proteins., PLoS One, 2011, 6, e26325.
18) Berg J. M. and Shi Y. The galvanization of biology: a growing appreciation for the role of zinc., Science, 1996, 271, 1081-1085.
19) Gamsjaeger R., Liew C. K., Loughlin F. E., Crossley M. and Mackay J. P. Sticky fingers: zincfingers as protein-recognition motifs, Trends Biochem. Sci., 2007, 32, 63-70.
20) Krishna S. S., Majumdar I. and Grishin N. V. Structural classification of zinc fingers: survey and summary., Nucleic Acids Res., 2003, 31, 532-550.
21) Keilin D. and Mann T. Carbonic anhydrase. Purification and nature of the enzyme., Biochem. J., 1940, 34, 1163-1176.
22) 松井利郎. レニン-アンジオテンシン系と血圧調節. 化学と生物, 2015, 53, 228-235.
23) Fyhrquist F. and Saijonmaa O. Renin-angiotensin system revisited., J. Int. Med., 2008, 264, 224- 236.
24) 高血圧治療ガイドライン;日本高血圧学会 2014
25) Ondetti M. A., Rubin B. and Cushman D. W. Design of specific inhibitors of angiotensin converting enzyme; New class of orally active antihypertensive agents., Science, 1977, 196, 441- 444.
26) Natesh R., Schwager S. L. U., Evans H. R., Sturrock E. D. and Acharya K. R. Structural details on the binding of antihypertensive drugs Captopril and Enalaprilat to human testicular Angiotensin Iconverting enzyme., Biochemistry, 2004, 43, 8718-8724.
27) Natesh R., Schwager S. L. U., Sturrock E. D. and Acharya K. R. Crystal structure of the human Angiotensin-converting enzyme-lisinopril complex., Nature, 2003, 421, 551-554.
28) Andreini C., Banci L., Bertini I., Rosato A. Zinc through the three domains of life., J. Proteome Res., 2006, 5, 3173-3178.
29) Coleman J. E. Zinc proteins: enzyme, storage proteins, transcription factors, and replication proteins., Annu. Rev. Biochem., 1992, 61, 897-946.
30) South T. I., Blake P. R., Sowder III R. C. Arthur I. O., Henderson L. E. and Summers M. F. The nucleocapsid protein isolated from HIV-1 particles bind zinc and forms retroviral-type zinc fingers., Biochemistry, 1990, 29, 7786-7789.
31) Omichinski J. G., Clore G. M., Sakaguchi K., Appella E. and Gronenborn M. Structural characterization of a 39-residue synthetic peptide containing the two zinc binding domains from the HIV-1 p7 nucleocapsid protein by CD and NMR spectroscopy., FEBS Lett., 1991, 292, 25-30.
32) Morellet N., Julian N., De Rocquigny H., Maigret B., Darlix J. I. and Roques B. P. Determination of the structure of the nucleocapsid protein NCp7 from the human immunodeficiency virus type 1 by 1H NMR., EMBO J., 1992, 11, 3059-3065.
33) De Guzman R. N., Wu Z. R., Stalling C. C., Pappalardo L., Borer P. N. and Summers M. F. Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element., Science, 1998, 279, 384-388.
34) Nyamweya S., Hegedus A., Jaye A., Rowland-Jones S., Flanagan K. L. and Macallan D. C. Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis., Rev. Med. Virol., 2013, 23, 221-240.
35) 野間口雅子, 足立昭夫 アクセサリー蛋白質と抗 HIV 細胞因子., ウイルス, 2009, 59, 67- 74.
36) Fujita M., Nomaguchi M., Adachi A. and Otsuka M. SAMHD1-dependent and -independent function of HIV-2/SIV Vpx protein., Front. Microb., 2012, 3, 297.
37) Sauter D. and Kirchhoff F. Multilayered and versatile inhibition of cellular antiviral factors by HIV and SIV accessory proteins., Cytokine and Growth Factor Rev., 2018, 40, 3-12.
38) Khamsri B., Murao F., Yoshida A., Sakurai A., Uchiyama., Shirai H., Matsuo Y., Fujita M. and Adachi A. Comparative study on the structure and cytopathogenic activity of HIV Vpr/Vpx proteins., Microb. Infect., 2006, 8, 10-15.
39) Wecker. K., Morellet N., Bouaziz S. and Roques B. P. NMR structure of the HIV-1 regulatory protein Vpr in H2O/trifluoroethanol. Comparison with the Vpr N-terminal (1-51) and C-terminal (52-96) domain., Eur. J. Biochem., 2002, 269, 3779-3788.
40) Wu. Y., Zhou X., Barnes C. O., DeLucia M., Cohen A. E., Gronenborn A. M., Ahn J. and Calero G. The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction., Nat. Struct. Mol. Biol., 2016, 10, 933-940.
41) Schwefel D., Groom H. C. T., Boucherit V. C., Christodoulou E., Walker P. A. Stoye J. P., Bishop K. N. and Taylor I. A. Structural basis of lentiviral subversion of a cellular protein degradation pathway., Nature, 2014, 505, 234-238.
42) Yamamoto M., Koga R., Fujino H., Shimagaki K., Ciftci H. I., Kamo M., Tateishi H., Otsuka M. and Fujita M. Zinc-binding site of human immunodeficiency virus 2 Vpx prevents instability and dysfunction of the protein., J. Gen. Virol., 2017, 98, 275-283.
43) Kewalramani V. N., Park C. S., Gallombardo P. A. and Emerman M. Protein Stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect., Virology, 1996, 218, 326-334.
44) Hasegawa A., Tsujimoto H., Maki K., Ishikawa K., Miura T., Fukasawa M., Miki K. and Hayami M, Genomic divergence of HIV-2 from Ghana., AIDS Res. Hum. Retroviruses., 1989, 5, 593-604.
45) Fujita M., Otsuka M., Miyoshi M., Khamsri B., Nomaguchi M. and Adichi A. Vpx is crucial for reverse transcription of the human immunodeficiency virus type 2 genome in macrophage., J. Virol., 2008, 8, 7752-7756.
46) Clavel F., Guyader M., Guétard D., Sallé M. Montagunier L. and Alizon M. Molecular cloning and polymorphism of the human immune deficiency virus type 2., Nature, 1986, 324, 691-695.
47) Ibe S., Yokomaku Y., Shiino T., Tanaka R., Hattori J. Fujisaki S., Iwatani Y., Mamiya N., Utsumi M. Kato S. et. al. HIV-2 CRF01_AB: first circulating recombinant form of HIV-2., J. Acquir. Immune Defic. Syndr., 2010, 54, 241-247.
48) Kestler H., Kodama T., Ringler D., Marthas M., Pedersen N., Lackner A., Regier D., Sehgal P., Daniel M. and King N. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus., Science, 1990, 248, 1109-1112.
49) Regier D. A. and Desrosiers R. C. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus., AIDS Res. Hum. Retroviruses, 1990, 6, 1221-1231.
50) Adachi A., Gendelman H. E., Koenig S., Folks T., Wiley R., Rabson A. and Martin M. A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone., J. Virol., 1986, 59, 284-291.
51) Hirsch V. M., Dapolito G., Johnson P. R., Elkins W. R., London W. T., Montali R. J., Goldstein S. and Brown C. Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication., J. Virol., 1995, 69, 955-967.
52) Bibollet-Ruche F., Bailes E., Gao F., Pourrut X., Barlow, K. L., Clewley J. P., Mwenda J. M., Langat D. K., Chege G. K., McClure H. M., Mpoudi-Ngole E., Delaporte E., Peeters M., Shaw G. M., Sharp P. M. and Hahn B. H. New simian immunodeficiency virus infecting De Brazza’s monkeys (Cercopithecus neglectus): evidence for a Cercopithecus monkey virus clade., J Virol., 2004, 78, 7748-7762.
53) Hirsch V. M., Campbell B. J., Bailes E., Goeken R., Brown C., Elkins W. R., Axthelm M., Murphey-Corb M. and Sharp P. M. characterization of a novel simian immunodeficiency virus (SIV) from L’ Hoest monkeys (Cercopithecus l’hoesti): implication for the origins of SIVmnd and other primate lentiviruses., J. Virol., 1999, 73, 1036-1045.
54) Miyake A., Fujita M., Fujino H., Koga R., Kawamura S., Otsuka M., Ode H., Iwatani Y., Sakai Y., Doi N., Nomaguchi M., Adachi A. and Miyazaki Y. Poly-proline motif in HIV-2 Vpx is critical for its efficient translation., J. Gen. Virol., 2014, 95, 179-189.
55) Accola M. A., Bukovsky A. A., Jones M. S. and Göttlinger H. G. A conserved dileucine-containing motif in p6gag governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIVmac and SIVagm. J. Virol., 1999.73, 9992-9999.
56) Kawamura M., Sakai H and Adachi A. Human immunodeficiency virus Vpx is required for the early phase of replication in peripheral blood mononuclear cells., Microb. Infect., 1994, 38, 871- 878.
57) Krebs F. C., Hogan T. H., Quiterio S., Gartner S. and Wigdahl B. Lentiviral LTR-directed expression, sequence variation, and disease pathogenesis., HIV Sequence Compendium 2001, pp29
58) Kanemaru Y., Momiki Y., Matsuura S., Horikawa T., Gohda J., Inoue J., Okamoto Y., Fujita M. and Otsuka M., An artificial copper complex incorporating a cell-penetrating peptide inhibitors nuclear factor-B (NF-B) activation., Chem. Pharm. Bull., 2011, 59, 1555-1558.
59) Ueno F., Shiota H., Miyaura M., Yoshida A., Sakurai A., Tatsuki J., Koyama A. H., Adachi A. and Fujita M. Vpx and Vpr proteins of HIV-2 up-regulate the viral infectivity by a distinct mechanism in lymphocytic cells., Microb. Infect., 2003, 5, 387-395.
60) Laguette N., Brégnard C., Hue P., Basbous J., Yatim A., Larroque M., Kirchhoff F., Constantinou A., Sobhian B. and Benkirane M. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing., Cell, 2014, 156, 134-145.
61) Romani B., Baygloo N. S., Aghasadeghi M. R. and Allahbakhshi E. HIV-1 Vpr protein enhances proteasomal degradation of MCM10 DNA replication fctor through the Cul4-CCB1[VprBP] E3 ubiquitin ligase to ligase to induce G2/M cell cycle arrest., J. Biol. Chem., 2015, 290, 17380- 17389.
62) Romani B., Baygloo N. S., Hamidi-Fard M., Aghasadeghi M. R. and Allahbakhshi E. HIV-1 Vpr protein induces proteasomal degradation of Chromatin-associated class I HDACs to overcome latent infection of macrophages., J. Biol. Chem., 2016, 291, 2696-2711.
63) Hrecka K., Hao C., Shun M., Kaur S., Swanson S. K., Florens L., Washburn M. P. And Skowronski J. HIV-1 and HIV-2 exhibit divergent interactions with HLTF and UNG2 DNA repair proteins., Proc. Natl. Acad. Sci. U. S. A., 2016, 113, E3921-3930.
64) Lv L., Xu Y., Tsao L., Nakagawa T., Guo H., Su L. and Xiong Y. Vpr targets TET2 for degradation by CRL4VprBP E3 kinase to sustain IL-6 expression and enhance HIV-1 replication., Mol. Cell, 2018, 70, 961-970.
65) Kirkpartrik D. S., Hathaway N. A., Hanna J., Elsasser S., Rush J., Finley D., King R. W. and Gygi S. P. Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology., Nat. Cell Biol., 2006, 8, 700-710.
66) Lu Y., Wang W. and Kirschner M. W. Specificity of the anaphase-promoting complex: A singlemolecule study., Science, 2015, 348, 1248737.
67) Lu Y., Lee B. H., King R. W., Finley D. and Kirschner M. W. Substrate degradation by the proteasome: A single-molecule kinetic analysis., Science, 2015, 348, 1250834.
68) 佐伯泰. プロテアソームの作動機構と細胞内動態. 生化学, 2015, 87, 705-722.
69) Wang H., Guo H., Su J., Rui Y., Zhang W., Gao W., Zhang W., Li Z., Jiu G., Markham R. B. Wei W. and Yu X-F. Inhibition of Vpx-Mediated SAMHD1 and Vpr-mediated host helicase transcription factor degradation by selective disruption of viral CRL4 (DCAF1) E3 ubiquitin ligase assembly. J. Virol., 2017, 91, e00225-17.
70) Zhao J. Z., Wang L., Mukherjee S. and Narayan. Biochemical Mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain., J. Biol. Chem., 1994, 269, 32131-32137.
71) Ciftci H. I., Fujino H., Koga R., Yamamoto M., Kawamura S., Tateishi H., Iwatani Y., Otsuka M. and Fujita M. Mutational analysis of HIV-2 Vpx shows that proline residue 109 in the poly-proline motif regulates degradation of SAMHD1., FEBS Lett., 2015, 589, 1505-1514.
72) Fletcher III, T. M., Brichacek N.S., Sharova N., Newman M. A., Stivahtis G., Sharp P. M., Emerman M., Hahn B. H. And Stevenson M. Nuclear iport and cell cycle arrest functions of the HIV-1 Vpr proteins are encoded by two separate genes in HIV-2/SIVSM., EMBO J., 1996, 15, 6155-6165.
73) Lim E., Fregoso O. I., McCoy C. O., Matsen F. A., Malik H. S. And Emerman M. The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx., Cell Host Microbe., 2012, 11, 194-204.
74) Skaug B., Jiang X. and Chen Z. J. The role of ubiquitin in NF-B regulatory pathways., Annu. Rev. Biochem., 2009, 78, 769-796.
75) Walsh MC., Lee J. and Choi Y. Tumor necrosis factor receptor-associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system., Immunol. Rev., 2015, 266, 72-92.
76) Inoue J., Gohda J. and Akiyama T. Characteristics and biological functions of TRAF6., Adv. Exp. Med. Biol., 2007, 597, 72-79.
77) Lamothe B., Besse A., Campos A. D., Webster W. K., Wu H. and Darnay B. G. Site-specific Lys63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of IB kinase activation., J. Biol. Chem., 2007, 282, 4102-4112.
78) Swatek K. N. And Komander D. Ubiquitin modifications., Cell Res., 2016, 26, 399-422.
79) Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C., Pickart C. and Chen Z. J. Activation of the IB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain., Cell, 2000, 103, 351-361.
80) Sun L., Deng L., Ea C. K., Xia Z. P. And Chen Z. J. The TRAF6 ubiquitin and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocyte., Mol. Cell, 2004, 14, 289-301.
81) Gohda J., Irisawa M., Tanaka Y., Sato., Ohtani K., Fujisawa J. and Inoue J. HTLV-1 Tax-induced NFB activation is independent of Lys-63-linked-type polyubiuquitination., Biochem. Biophys. Res. Commun., 2007, 357, 225-230.
82) Fan Y., Yu Y., Shi Y., Sun W., Xie M., Ge N., Mao R., Chang A., Xu G., Schneider M. D., Zhang H., Fu S., Qin J. and Yang J. Lysine 63-linked polyubiquitination of TAK1 at lysine158 is required for tumor necrosis factor and interleukin- induced IKK/NF-B and JNK/AP-1 activation., J. Biol. Chem., 2010, 285, 5347-5360.
83) Yamasaki K., Gohda J., Kanayama A., Miyamoto Y., Sakurai H., Yamamoto M., Akira S., Hayashi H., Su B. and Inoue J. Two mechanistically and temporally distinct NF-B activation pathways in IL-1 signaling., Sci. Signal., 2009, 2, ra66.
84) Sebban-Benin H., Pescatore A., Fusco F., Pascuale V., Gautheron J., Yamaoka., Moncla A., Ursini M. V. and Courtois G. Hum. Mol. Genet., 2007, 16, 2805-2815.
85) Ishida T. Mizushima S., Azuma S., Kobayashi N., Tojo T., Suzuki K., Aizawa S., Watanabe T., Misialos G., Kieff E., Yamamoto T. and Inoue J. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region., J. Biol. Chem., 1996, 271, 28745-28748.
86) Lamothe B., Campos A. D., Webster W. K., Gopinathan A., Hur L. and Darnay G. The ring domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, Lipopolysaccharide and RANKL., J. Biol. Chem., 2008, 283, 24871-24880.
87) Yin Q., Lin S. C., Lamothe B., Lu M., Lo Y. C., Hura G., Zhang L., Rich R. L., Campos A. D., Myszka D. G., Lenardo M. J., Darnay B. G. and Wu H. E2 interaction and dimerization in the crystal structure of TRAF6., Nat. Struct. Mol. Biol., 2009, 16, 658-666.
88) Fujita M., Otsuka M. and Sugiura Y. Metal-chelating inhibitors of a zinc finger protein HIV-EP1. Remarkable potentiation of inhibitory activity by introduction of SH groups., J. Med. Chem., 1996, 39, 503-507.
89) Maekawa T., Sakura H., Sudo T. and Ishii S. Putative metal finger structure of the human immunodeficiency virus type 1 enhancer binding protein HIV-EP1., J. Biol. Chem., 1989, 264, 14591-14593.
90) Otsuka M., Fujta M., Sugiura Y., Yamamoto T. and Inoue J. Synthetic inhibitors of regulatory proteins involved in the signaling pathway of the replication of human immunodeficiency virus 1., Bioorg. Med. Chem., 1997, 5, 205-215.
91) Hamasaki A., Naka H., Tamanoi F., Umezawa K. and Otsuka M. A novel metal-chelating inhibitor of protein Farnesyltransferase., Bioorg. Med. Chem. Lett., 2003, 13, 1523-1526.
92) Tanaka A., Radwan M. O., Hamasaki A., Ejima T., Obata E., Koga R., Tateishi., Okamoto Y., Fujita M., Nakao M., Umezawa K., Tamanoi F. and Otsuka M. A Novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group., Bioorg. Med. Chem. Lett., 2017, 27, 3862-3866.
93) Ejima T., Hirota M., Muzukami T., Otsuka M. and Fujita M. An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G., Int. J. Mol. Med., 2011, 28, 613-616.
94) Radwan M. O., Sonoda S., Ejima T., Tanaka A., Koga R., Yoshinari O., Fujita M. and Otsuka M. Zinc-mediated binding of a low-molecular-weight stabilizer of the host anti-viral factor apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G., Bioorg. Med. Chem., 2016, 24, 4398-4405.
95) Wertz I. E. and Dixit V. M. Signaling to NF-B: regulation by ubiquitination., Cold Spring Harb. Perspect. Biol., 2010, 3, a003350.
96) Petroski MD., Zhou X., Dong G. Q., Daniel-Issakani S., Payan D. G. and Huang J. Substrate modification with lysine 63-linked ubiquitin chains through the UBC13-UEV1A ubiquitinconjugating enzyme., J. Biol. Chem., 2007, 282, 29936-29945.
97) Middleton A. J., Budhidarmo R., Das A., Zhu J., Foglizzo M., Mace P. D., Day C. L. The activity of TRAF RING homo- and heterodimers is regulated by zinc finger 1., Nat. Commun., 2017, 8, 1788.
98) Fu T. M., Shen C., Li Q., Zhang P. and Wu H. Mechanism of ubiquitin transfer promoted by TRAF6., Proc. Natl. Acad. Sci. U. S. A., 2018, 115, 1783-1788.
99) Hu L., Xu J., Xie X., Zhou Y., Tao P., Li H., Han X., Wang C., Liu J., Xu P., Neculai D. and Xia Z. Oligomerization-primed coiled-coil domain interaction with Ubc13 confers processivity to TRAF6 ubiquitin ligase activity., Nat. Commun., 2017, 8, 814.
100) Qi Y., Pradipta AR., Li M., Zhao X., Lu L., Fu X., Wei J., Hsung R. P., Tanaka K. and Zhou L. Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6., J. Exp. Clin. Cancer Res., 2017, 36, 35-
101) Brenke JK., Popowicz G. M., Schorpp K., Rothenaigner I., Roesner M., Meininger I., Kalinski C., Ringelstetter L., R’kyek O., Jürjens G., Vincendeau M., Plettenburg O., Sattler M., Krappmann D. and Hadian K. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity., J. Biol. Chem., 2018, 293, 13191-13203.
102) Hänel K., Möckel L., Brummel M., Peiris K., Hartnmann R., Dingley A., Willbold D. and LoidlStahlhofen A. Expression and purification of soluble HIV-2 viral protein R (Vpr) using a sandwich-fusion protein strategy., Protein Expr. Purif., 2014, 95, 156-161.
103) Eijkelenboom A. P. A. M., van den Ent F. M. I., Vos A., Doreleijers J. F., Hård K., Tullius T. D., Plasterk R. H. A., Kaptein R. and Boelens R. The solution structure of the amino-terminal HHCC domain of HIV-2 integrase: a three-helix bundle stabilized by zinc., Curr. Biol, 1997, 7, 739-746.
104) Chen Q., Chen T., Li W., Zhang W., Li Y., Huang Y., Shen Y. and Yu C. Mycoepoxydiene inhibits lipopolysaccharide-induced inflammatory responses through the of TRAF6 polyubiquitination., PLoS One, 2012, 7, e44890.
105) Chiou W. F., Huang Y. L. and Liu Y. W. (+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation., PLoS One, 2014, 9, e89159.
106) Inoue J., Gohda J., Akiyama T. and Semba K. NF-kappaB activation in development and progression of cancer., Cancer Sci., 2007, 98, 268-274.
107) Sun H., Li X. B., Meng Y., Fan L., Li M. and Jing F. TRAF6 upregulates expression of HIF-1 and promotes tumor angiogenesis., Cancer Res., 2013, 73, 4950-4959.
108) Gudey SK., Sunder R., Mu Y., Wallenius A., Zang G., Bergh A., Heldin C. Landström M. TRAF6 stimulates the tumor-promoting effects of TGF type I receptor through polyubiquitination and activation of presenilin 1., Sci. Signal., 2014, 7, ra2.
109) Kumar S., Stecher G. and Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets., Mol. Biol. Evol., 2016, 33, 1870-1874.
110) Shibata Y., Oyama M., Kozaka-Hata H., Han X., Tanaka Y., Gohda J. and Inoue J., p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO., Nat. Commun., 2012, 3, 1061.
111) Fukuchi M., Imamura T., Chiba T., Ebisawa T., Kawabata M., Tanaka K. and Miyazono K., Mol. Biol. Cell., 2001, 12, 1431-1443.